Biotech & Pharma

Biogen completed acquisition of RayThera Inc., with the acquired company's lead program now in Phase 1 development.

Leadership read: Consolidation shifts the leadership question from growth to integration. For Biogen in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-08-06 · context →

Federal judge approved $35M settlement with healthcare funds over allegations Teva delayed generic versions of asthma inhalers, causing higher prices

Leadership read: Consolidation shifts the leadership question from growth to integration. For Teva Pharmaceuticals in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-08-06 · context →

Twist Bioscience priced a $300 million stock offering at $96 per share, indicating successful capital raise in public markets.

Leadership read: Twist Bioscience's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.

curated · 2026-08-05 · context →

Flagship Pioneering, a scientific innovation engine, appointed two Executive Partners: Fidah Alsagoff (Head of Global Initiatives) and Maggie Sahlman (Head of Fundraising and Investor Relations).

Leadership read: A change at the top rarely stays at the top. Flagship Pioneering's move reshapes the layer beneath it in Biotech & Pharma as a new leader sets priorities and the team re-forms. Watch the first two or three appointments that follow; they signal direction more reliably than any statement.

curated · 2026-08-03 · context →

Bristol Myers Squibb is in merger talks with AstraZeneca regarding a potential $400 billion megadeal

Leadership read: Consolidation shifts the leadership question from growth to integration. For Bristol Myers Squibb in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-08-02 · context →

Ratio Therapeutics closed a Series C funding round of $70M for radiopharmaceutical trials, led by existing investors Duquesne Family Office and Bristol Myers Squibb, with new investor participation.

Leadership read: Ratio Therapeutics's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.

curated · 2026-07-31 · context →

Teva Pharmaceuticals CEO Richard Francis discusses Q2 earnings, drug pipeline, and the company's direct listing on NYSE. Signals leadership visibility and capital market transition.

Leadership read: A change at the top rarely stays at the top. Teva Pharmaceuticals's move reshapes the layer beneath it in Biotech & Pharma as a new leader sets priorities and the team re-forms. Watch the first two or three appointments that follow; they signal direction more reliably than any statement.

curated · 2026-07-29 · context →

Amgen is advancing MariTide, a monthly weight-loss injection, through 6 Phase 3 trials as a direct competitor to Eli Lilly and Novo Nordisk's weekly GLP-1 drugs. The product is positioned to enter the market with a convenience advantage.

Leadership read: Amgen's launch shifts talent demand before revenue catches up. In Biotech & Pharma, taking a release to scale rewards product leaders with a commercial edge and operators who build the post-launch motion. Watch whether Amgen backs it with senior go-to-market hires across Americas — that separates a platform move from a one-off.

curated · 2026-07-29 · context →

Biogen is relying on drugs acquired through the Apellis deal to offset weak sales of Leqembi (Alzheimer's drug), indicating strategic dependence on M&A to bolster pipeline performance.

Leadership read: Consolidation shifts the leadership question from growth to integration. For Biogen in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Americas, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-07-23 · context →

Bristol Myers Squibb announced a partnership with Nvidia to build an advanced AI supercomputer system for drug discovery and development, positioning it as the most advanced and energy-efficient system in biopharma.

Leadership read: Alliances broaden the commercial surface, and the leadership need follows. Bristol Myers Squibb's partnership in Biotech & Pharma widens demand for commercial and alliance leaders who turn an agreement into realised value. Across Americas, watch whether dedicated senior ownership is put on it; unowned alliances quietly lapse.

curated · 2026-07-20 · context →

Boehringer Ingelheim reported first-half 2026 sales growth of 16.2% (EUR 15.8 billion), driven by strong U.S. performance including increased demand for JARDIANCE® and successful new product launches.

Leadership read: A product move like this reshapes Boehringer Ingelheim's org chart as much as its roadmap. Scaling in Biotech & Pharma rests on product leadership that can carry a launch to adoption and commercial hires who turn early traction into pipeline. The Americas tell is whether senior GTM appointments follow; unsupported launches stall.

curated · 2026-07-15 · context →

Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.

Leadership read: Consolidation shifts the leadership question from growth to integration. For Teva Pharmaceuticals in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Oceania, watch whether the integration is properly resourced; deals are won or lost the year after they close.

curated · 2026-07-14 · context →